AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10880165 — intervention group
Group type: COMPARATOR
Intervention: Potassium magnesium aspartate for four weeks
Number of subjects: 110
Study 8932837 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (120 mg/kg), mitoxantrone (60 mg/m2), and melphalan (140 mg/m2) followed by autologous bone marrow transplantation (ABMT)
Number of subjects: 61
Study 8932837 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (120 mg/kg), mitoxantrone (60 mg/m2), and melphalan (140 mg/m2) followed by ABMT
Number of subjects: 61
Study 1559530 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Training (RT)
Number of subjects: 81
Study 1559530 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG Biofeedback
Number of subjects: 81
Study 1559530 — intervention group
Group type: EXPERIMENTAL
Intervention: ST Biofeedback
Number of subjects: 81
Study 1559530 — intervention group
Group type: COMPARATOR
Intervention: No Biofeedback
Number of subjects: 81
Study 1559530 — intervention group
Group type: COMPARATOR
Intervention: No RT
Number of subjects: 81
Study 3887165 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle paralysis
Number of subjects: 24
Study 3887165 — intervention group
Group type: COMPARATOR
Intervention: Control (no muscle paralysis)
Number of subjects: 24
Study 31101371 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry-funded trials
Number of subjects: 114
Study 31101371 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistically significant subgroup analysis
Number of subjects: 114
Study 31101371 — intervention group
Group type: EXPERIMENTAL
Intervention: Claiming accomplishment of an objective not prespecified
Number of subjects: 114
Study 31481105 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission achieved and maintained
Number of subjects: 841
Study 31481105 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical atherosclerosis
Number of subjects: 841
Study 31481105 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical atherosclerosis
Number of subjects: 841
Study 31481105 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (T2D)
Number of subjects: 841
Study 31481105 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood pressure
Number of subjects: 841
Study 31481105 — intervention group
Group type: EXPERIMENTAL
Intervention: ACPA
Number of subjects: 841
Study 31481105 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean values of CRP during follow-up
Number of subjects: 841
Study 28505956 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐invasive Spinal Decompression Therapy (NSDT)
Number of subjects: 20
Study 28505956 — intervention group
Group type: COMPARATOR
Intervention: Combination of electrotherapy, deep friction massage, and stabilization exercise (Control Group)
Number of subjects: 20
Study 25384624 — intervention group
Group type: EXPERIMENTAL
Intervention: Split virion vaccine
Number of subjects: 156
Study 25384624 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole virion vaccine
Number of subjects: 156
Study 25384624 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 156
Study 25384624 — intervention group
Group type: EXPERIMENTAL
Intervention: Split virion vaccine with anti-TNF-α therapy
Number of subjects: 156
Study 25384624 — intervention group
Group type: EXPERIMENTAL
Intervention: Postimmunization
Number of subjects: 156
Study 25384624 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated patients
Number of subjects: 156
Study 23068310 — intervention group
Group type: EXPERIMENTAL
Intervention: sucking-oral sucrose-tucking
Number of subjects: 110
Study 23068310 — intervention group
Group type: EXPERIMENTAL
Intervention: sucking-oral sucrose
Number of subjects: 110
Study 23068310 — intervention group
Group type: EXPERIMENTAL
Intervention: oral sucrose-tucking
Number of subjects: 110
Study 23068310 — intervention group
Group type: EXPERIMENTAL
Intervention: sucking-tucking
Number of subjects: 110
Study 23068310 — intervention group
Group type: COMPARATOR
Intervention: routine care
Number of subjects: 110
Study 21805066 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 129
Study 21805066 — intervention group
Group type: COMPARATOR
Intervention: Roxatidine
Number of subjects: 129
Study 19366972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glulisine insulin
Number of subjects: 68
Study 19366972 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous glargine and glulisine
Number of subjects: 68
Study 19366972 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous NPH and regular insulin
Number of subjects: 68
Study 16738027 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy
Number of subjects: 0
Study 16738027 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy in ingroup condition
Number of subjects: 0
Study 15305945 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of inhaled budesonide
Number of subjects: 18
Study 15305945 — intervention group
Group type: COMPARATOR
Intervention: Continuous treatment with inhaled budesonide
Number of subjects: 18
Study 11321648 — intervention group
Group type: EXPERIMENTAL
Intervention: Days of raised geomagnetic activity
Number of subjects: 0
Study 11321648 — intervention group
Group type: COMPARATOR
Intervention: Days of little or no sun activity (quiet sun)
Number of subjects: 0
Study 9386112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vasopressin (0.1 U/min)
Number of subjects: 10
Study 9386112 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 10
Study 9386112 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded vasopressin (in crossover subjects)
Number of subjects: 10
Study 9386112 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin in low vasopressin group (n=5)
Number of subjects: 10
Study 9386112 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin in high vasopressin group (n=3)
Number of subjects: 10
Study 7910053 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with thymosin alpha 1, interferon-alpha, and zidovudine
Number of subjects: 0
Study 7910053 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine alone or associated with single agents
Number of subjects: 0
Study 3064642 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (100 mg/day) for 10 days
Number of subjects: 69
Study 3064642 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules for 10 days
Number of subjects: 69
Study 3064642 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholics with subnormal serum alpha-tocopherol
Number of subjects: 69
Study 3064642 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholics and controls
Number of subjects: 69
Study 29347848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal oxytocin gel
Number of subjects: 140
Study 29347848 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 140
Study 26514296 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific exercises (NSEs)
Number of subjects: 41
Study 26514296 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (WL)
Number of subjects: 41
Study 24793567 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone, 60mg/day
Number of subjects: 10
Study 24793567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 24173178 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% diclofenac sodium
Number of subjects: 28
Study 24173178 — intervention group
Group type: COMPARATOR
Intervention: 5% 5-Fluorouracil
Number of subjects: 28
Study 20921032 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-intensity treadmill walking (30 minutes, three times per week for six weeks)
Number of subjects: 30
Study 20921032 — intervention group
Group type: COMPARATOR
Intervention: Usual physiotherapy
Number of subjects: 30
Study 19595100 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation technique (navigation group)
Number of subjects: 95
Study 19595100 — intervention group
Group type: COMPARATOR
Intervention: Conventional anatomic landmark technique (conventional group)
Number of subjects: 95
Study 19595100 — intervention group
Group type: EXPERIMENTAL
Intervention: General fitness rate
Number of subjects: 95
Study 19595100 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw canal preparation time
Number of subjects: 95
Study 19595100 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 95
Study 17046545 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured triglyceride (STG) emulsion (Structolipid 20%)
Number of subjects: 8
Study 17046545 — intervention group
Group type: COMPARATOR
Intervention: Long-chain fatty acid triglyceride (LCT) emulsion (Intralipid 20%)
Number of subjects: 8
Study 12734858 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrografin (100 ml)
Number of subjects: 83
Study 12734858 — intervention group
Group type: COMPARATOR
Intervention: Control group (conservative treatment)
Number of subjects: 83
Study 10647721 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ml intracameral, unpreserved, epinephrine‐free 1% lidocaine
Number of subjects: 200
Study 10647721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 9052889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrabrachial acetylcholine (0.15, 0.45, 1.5, 4.5, and 15 microg/100 mL per minute)
Number of subjects: 90
Study 9052889 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (1 micromol/100 mL per minute)
Number of subjects: 90
Study 9052889 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 microg/100 mL per minute)
Number of subjects: 90
Study 9052889 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (1, 2, and 4 microg/100 mL per minute)
Number of subjects: 90
Study 9052889 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 90
Study 9052889 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 90
Study 8346005 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent cold‐adapted recombinant influenza vaccine
Number of subjects: 68
Study 2954872 — intervention group
Group type: EXPERIMENTAL
Intervention: Buddy programme
Number of subjects: 100
Study 2954872 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 29880148 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep extension (EXT)
Number of subjects: 18
Study 26549496 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic attachment (group I, GI)
Number of subjects: 32
Study 26549496 — intervention group
Group type: COMPARATOR
Intervention: Locator attachment (group II, GII)
Number of subjects: 32
Study 26549496 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (GI and GII)
Number of subjects: 32
Study 25394440 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (50 μg) and normal saline (10 mL)
Number of subjects: 50
Study 25394440 — intervention group
Group type: COMPARATOR
Intervention: Epidural fentanyl (50 μg) and bupivacaine (0.5%; 10 mL)
Number of subjects: 50
Study 23328343 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary program consisting of cognitive-behavior therapy and exercise training
Number of subjects: 90
Study 23328343 — intervention group
Group type: COMPARATOR
Intervention: Exercise training alone
Number of subjects: 90
Study 16154423 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 7
Study 16154423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 12858034 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 12
Study 12858034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9469675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 20 mg administered under fasting conditions (treatment A)
Number of subjects: 8
Study 9469675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 20 mg administered directly after a standard high-fat breakfast (treatment B)
Number of subjects: 8
Study 9469675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 20 mg administered 2 hours after a standard high-fat breakfast (treatment C)
Number of subjects: 8
Study 8674522 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling program for family caregivers
Number of subjects: 0
Study 8674522 — intervention group
Group type: COMPARATOR
Intervention: Traditional counseling dimensions (education, emotional expressiveness)
Number of subjects: 0
Study 1964073 — intervention group
Group type: EXPERIMENTAL
Intervention: CEV (etoposide + vindesine + cisplatin)
Number of subjects: 201
Study 1964073 — intervention group
Group type: COMPARATOR
Intervention: EV (etoposide + vindesine)
Number of subjects: 201
Study 369966 — intervention group
Group type: EXPERIMENTAL
Intervention: Native gammaglobulin
Number of subjects: 0
Study 369966 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-treated gammaglobulin
Number of subjects: 0
Study 28614492 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS applied over the right DLPFC (1 Hz, n=15)
Number of subjects: 29
Study 28614492 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS applied over the left DLPFC (5 Hz, n=14)
Number of subjects: 29
Study 27424688 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 22 mg/kg/day
Number of subjects: 81
Study 27424688 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA) 2 mg/kg/day
Number of subjects: 81
Study 27424688 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 81
Study 27424688 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 81
Study 27424688 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MMF and AZA
Number of subjects: 81
Study 24729492 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV)
Number of subjects: 0
Study 24729492 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 0
Study 24246459 — intervention group
Group type: EXPERIMENTAL
Intervention: Fisher & Paykel Healthcare (FPH) CPAP interface
Number of subjects: 20
Study 24246459 — intervention group
Group type: COMPARATOR
Intervention: Hudson CPAP interface
Number of subjects: 20
Study 20430115 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual primary prevention care plus bespoke lifestyle support (treatment)
Number of subjects: 920
Study 20430115 — intervention group
Group type: COMPARATOR
Intervention: Usual primary prevention care (control)
Number of subjects: 920
Study 18645188 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient ischemic cutaneous anesthesia of the healthy hand
Number of subjects: 10
Study 18645188 — intervention group
Group type: COMPARATOR
Intervention: Healthy foot (control intervention)
Number of subjects: 10
Study 15824870 — intervention group
Group type: EXPERIMENTAL
Intervention: Right, left, and biventricular stimulation at different AV delays
Number of subjects: 188
Study 15824870 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial-left ventricular stimulation
Number of subjects: 188
Study 15824870 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial-biventricular stimulation
Number of subjects: 188
Study 15824870 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after one year
Number of subjects: 188
Study 12438948 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (5 mg daily after a 15 mg loading dose, concentration-controlled to keep 24-hr trough levels at 10 to 12 ng/mL for 6 months and 5 to 10 ng/mL thereafter)
Number of subjects: 61
Study 12438948 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (6 to 8 mg/kg per day in divided doses, concentration-controlled to keep 12-hr troughs of 200 to 250 ng/mL)
Number of subjects: 61
Study 12198790 — intervention group
Group type: EXPERIMENTAL
Intervention: Tickling by the experimenter
Number of subjects: 35
Study 12198790 — intervention group
Group type: COMPARATOR
Intervention: Tickling by an automated machine
Number of subjects: 35
Study 7781416 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery combined with chemotherapy and radiotherapy
Number of subjects: 0
Study 7781416 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 7781416 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 7781416 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0
Study 2201320 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperimmune bovine colostrum
Number of subjects: 5
Study 2201320 — intervention group
Group type: COMPARATOR
Intervention: Control colostrum
Number of subjects: 5
Study 6104451 — intervention group
Group type: EXPERIMENTAL
Intervention: KWD 2131 (0.5 mg to 12 mg)
Number of subjects: 8
Study 6104451 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (0.05 mg to 1.2 mg)
Number of subjects: 8
Study 6104451 — intervention group
Group type: EXPERIMENTAL
Intervention: KWD 2131
Number of subjects: 8
Study 29594368 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually delivered social competence training (THAV)
Number of subjects: 91
Study 29594368 — intervention group
Group type: COMPARATOR
Intervention: Active control (PLAY)
Number of subjects: 91
Study 28239805 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop target controlled infusion (CLTCI) of cisatracurium
Number of subjects: 150
Study 28239805 — intervention group
Group type: COMPARATOR
Intervention: Muscle relaxation monitoring
Number of subjects: 150
Study 28239805 — intervention group
Group type: COMPARATOR
Intervention: Continuous pump injection
Number of subjects: 150
Study 25646323 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable foam (SF)
Number of subjects: 18
Study 25646323 — intervention group
Group type: EXPERIMENTAL
Intervention: Less-stable foam (LSF)
Number of subjects: 18
Study 25646323 — intervention group
Group type: COMPARATOR
Intervention: Liquid control (LC)
Number of subjects: 18
Study 23332034 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbicularis oculi muscle stripping
Number of subjects: 10
Study 23332034 — intervention group
Group type: COMPARATOR
Intervention: Skin-only blepharoplasty
Number of subjects: 10
Study 19966583 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-velocity (30° · s(‐1)) maximal lengthening contractions
Number of subjects: 18
Study 19966583 — intervention group
Group type: COMPARATOR
Intervention: Control group (single bout of fast-velocity exercise)
Number of subjects: 18
Study 19966583 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated bout group (first bout at 30° · s(‐1) and second bout at 210° · s(‐1))
Number of subjects: 18
Study 19436665 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 19436665 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0
Study 19436665 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (general)
Number of subjects: 0
Study 17364735 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost monotherapy
Number of subjects: 353
Study 15545949 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/Salmeterol (FP/S) combination
Number of subjects: 520
Study 15545949 — intervention group
Group type: COMPARATOR
Intervention: Treatment with a free combination of an inhaled corticosteroid and a long-acting beta2-agonist (TA)
Number of subjects: 520
Study 11489827 — intervention group
Group type: EXPERIMENTAL
Intervention: c-erbB-2 gene amplification
Number of subjects: 29
Study 11489827 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative increase in c-erbB-2 gene copy number
Number of subjects: 29
Study 11489827 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain of chromosome 17
Number of subjects: 29
Study 9731837 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg prostaglandin E2 intracervical gel (Prepidil) every 6 hours for 2 doses
Number of subjects: 90
Study 9731837 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg prostaglandin E2 slow release vaginal pessary (Cervidil)
Number of subjects: 90
Study 7984606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrahigh-frequency electromagnetic radiation (UHF) therapy combined with specific chemicals, 10 sessions using a YAVOR device at 6.4 and 7.1 mm.
Number of subjects: 54
Study 7984606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrahigh-frequency electromagnetic radiation (UHF) therapy combined with specific chemicals.
Number of subjects: 54
Study 7984606 — intervention group
Group type: COMPARATOR
Intervention: Control group (drug therapy alone).
Number of subjects: 54
Study 2722718 — intervention group
Group type: EXPERIMENTAL
Intervention: Latamoxef 2 g
Number of subjects: 29
Study 2722718 — intervention group
Group type: COMPARATOR
Intervention: Cefmetazole 2 g
Number of subjects: 29
Study 2722718 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 29
Study 798282 — intervention group
Group type: EXPERIMENTAL
Intervention: Early splenectomy
Number of subjects: 139
Study 798282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic chemotherapy with Arabinosyl Cytosine (ARA C), Vincristine, and Prednisone
Number of subjects: 139
Study 798282 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 139
Study 29574988 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain management educational intervention
Number of subjects: 152
Study 29574988 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 152
Study 29574988 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological methods
Number of subjects: 152
Study 28132007 — intervention group
Group type: EXPERIMENTAL
Intervention: ibobbly app (acceptance‐based therapy) over 6 weeks
Number of subjects: 61
Study 28132007 — intervention group
Group type: COMPARATOR
Intervention: waitlist for 6 weeks then ibobbly app for 6 weeks
Number of subjects: 61
Study 26346724 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirarubicin plus capecitabine (AX regimen)
Number of subjects: 280
Study 26346724 — intervention group
Group type: COMPARATOR
Intervention: Pirarubicin plus cyclophosphamide (AC regimen)
Number of subjects: 280
Study 23399428 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR mutations
Number of subjects: 151
Study 23399428 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 151
Study 20823239 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus
Number of subjects: 0